Cargando…

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants

VRC01 is being evaluated in the AMP efficacy trials, the first assessment of a passively administered broadly neutralizing monoclonal antibody (bnAb) for HIV-1 prevention. A key analysis will assess serum VRC01-mediated neutralization as a potential correlate of protection. To prepare for this analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yunda, Zhang, Lily, Eaton, Amanda, Mkhize, Nonhlanhla N., Carpp, Lindsay N., Rudnicki, Erika, DeCamp, Allan, Juraska, Michal, Randhawa, April, McDermott, Adrian, Ledgerwood, Julie, Andrew, Philip, Karuna, Shelly, Edupuganti, Srilatha, Mgodi, Nyaradzo, Cohen, Myron, Corey, Lawrence, Mascola, John, Gilbert, Peter B., Morris, Lynn, Montefiori, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Novel Vaccines – Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928800/ https://www.ncbi.nlm.nih.gov/pubmed/34213402 http://dx.doi.org/10.1080/21645515.2021.1908030

Ejemplares similares

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
por: Huang, Yunda, et al.
Publicado: (2021)

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
por: Magaret, Craig A., et al.
Publicado: (2019)

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
por: Seaton, Kelly E., et al.
Publicado: (2023)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
por: Huang, Yunda, et al.
Publicado: (2023)

1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisitionin in Uninfected Individuals
por: Edupuganti, Srilatha, et al.
Publicado: (2019)

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
por: Mkhize, Nonhlanhla N., et al.
Publicado: (2023)

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
por: Mayer, Kenneth H., et al.
Publicado: (2017)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
por: Huang, Yunda, et al.
Publicado: (2018)

Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap
por: Gray, Glenda E., et al.
Publicado: (2016)

Establishment of the 1st Chinese national standard for CA6 neutralizing antibody
por: Wang, Yiping, et al.
Publicado: (2023)

A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal
por: Chaudhary, Shipra, et al.
Publicado: (2023)

The applications of animal models in phage therapy: An update
por: Mehmood Khan, Fazal, et al.
Publicado: (2023)

Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial
por: Galgani, Ilaria, et al.
Publicado: (2023)

Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10–50 years old: Randomized, blinded, parallel controlled phase III clinical study
por: Huang, Xiaoyuan, et al.
Publicado: (2023)

Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial
por: López, Pio, et al.
Publicado: (2023)

Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally
por: Liao, Yun, et al.
Publicado: (2023)

Analysis and prediction of the incidence and prevalence trends of gonorrhea in China
por: Chen, Xueya, et al.
Publicado: (2023)

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
por: Patel, Sanjay S., et al.
Publicado: (2023)

Advancements in the development of nucleic acid vaccines for syphilis prevention and control
por: Li, Sijia, et al.
Publicado: (2023)

Acceptability for the influenza virus vector COVID-19 vaccine for intranasal spray: A cross-sectional survey in Beijing, China
por: Ma, Yuan, et al.
Publicado: (2023)

Challenges in development of vaccines directed toward antimicrobial resistant bacterial species
por: Brazzoli, Michela, et al.
Publicado: (2023)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)
por: Enama, Mary E., et al.
Publicado: (2014)

Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
por: Gilbert, Peter B., et al.
Publicado: (2022)

1558. Associations between gender identity and solicited adverse events after passive infusion of VRC01 or placebo in HVTN 704/HPTN 085
por: Theodore, Deborah, et al.
Publicado: (2023)

HIV-1 genetic diversity a challenge for AIDS vaccine development: a retrospective bibliometric analysis
por: Rashid, Abdur, et al.
Publicado: (2022)

Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments
por: Hraber, Peter, et al.
Publicado: (2017)

Characterization of T-Cell Responses to Conserved Regions of the HIV-1 Proteome in BALB/c Mice
por: Ondondo, Beatrice, et al.
Publicado: (2014)

Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention
por: Mahomed, Sharana, et al.
Publicado: (2022)

Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial
por: Mahomed, Sharana, et al.
Publicado: (2019)

Immune camouflage: Relevance to vaccines and human immunology
por: De Groot, Anne S, et al.
Publicado: (2014)

Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches
por: Absalon, Judith, et al.
Publicado: (2022)

Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses
por: Shoushtari, Mohammad, et al.
Publicado: (2022)

A strategic model for developing vaccines against neglected diseases: An example of industry collaboration for sustainable development
por: Berlanda Scorza, Francesco, et al.
Publicado: (2022)

Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa
por: Loxton, André G., et al.
Publicado: (2017)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
por: Lynch, RM, et al.
Publicado: (2012)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2018)

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants
por: Churchyard, Gavin, et al.
Publicado: (2016)

Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
por: Parks, K. Rachael, et al.
Publicado: (2019)

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_92umg2j3vab77no146vactphe1